People · Operator
Named in public records as an officer, director or promoter · active 2012–2025 · Software / Tech, Pharma, Other Health Care, Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Capital Integration Systems LLC | — | Software / Tech | Series D+ | $392.9M | $7.3B | 2020 |
| Halda Therapeutics, LLC | — | Pharma | Series D+ | $197.9M | $1.3B | 2019 |
| Rallybio Holdings, LLC | — | Other Health Care | Series D+ | $157.8M | $69.6M | 2020 |
| Arvinas, Inc. | — | Biotechnology | Series C | $129.1M | $1.3B | 2015 |
| Vivace Therapeutics, Inc. | — | Biotechnology | Series B | $60.5M | $93.8M | 2015 |
| Novira Therapeutics, Inc. | — | Pharmaceuticals | Series B | $48.0M | $306.0M | 2012 |
| Spyryx Biosciences, Inc. | — | Biotechnology | Series B | $29.1M | $235.4M | 2015 |
| Aer Therapeutics, Inc. | — | Biotechnology | Series B | $20.9M | $27.9M | 2022 |
| Arvinas, Inc. | — | Pharmaceuticals | Seed | $3.5M | $133.6M | 2013 |
Tim Shannon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Tim Shannon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kush Parmar | 3 | 10 |
| Christy Shaffer | 2 | 6 |
| Liam Ratcliffe | 2 | 4 |
| Jonathan Soderstrom | 2 | 3 |
| ANDREW LEVIN | 1 | 17 |
| Rishi Gupta | 1 | 12 |
| Ketan Patel | 1 | 10 |
| John Taylor | 1 | 10 |
| SCOTT ROCKLAGE | 1 | 9 |
| Matthew Brown | 1 | 9 |
| Stephen Squinto | 1 | 8 |
| Sean Cassidy | 1 | 7 |
| Jake Simson | 1 | 6 |
| Craig Crews | 1 | 6 |
| Arjun Goyal | 1 | 5 |
| Brian Daniels | 1 | 5 |
| Scott Phillips | 1 | 5 |
| Nandita Shangari | 1 | 4 |
| Scott M. Rocklage | 1 | 4 |
| Ronald M. Hunt | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.